Zelira Therapeutics (ASX:ZLD) has announced ethics approval has been granted for the Phase 2a clinical trial of its cannabinoid formulation, ZTL-106, in treating patients with chronic pain.
In June 2021, Zelira announced it had licensed ZTL-106 to Levin for the purpose of undertaking a clinical trial to test the efficacy of the formulation in treating sports-related chronic pain experienced by retired professional and amateur athletes.
Under the terms of the license agreement, Levin will provide the funding for the trial and Zelira will be contracted to project manage the trial.
The trial, which is undertaken in collaboration with La Trobe University’s Sport and Exercise Medicine Research Centre, will investigate the use of ZTL-106 as an effective medicinal cannabis drug in treating people with chronic pain specifically following musculoskeletal injury.
Professor Peter Brukner is the principal investigator for the trial.
Zelira Therapeutics managing director Dr Oludare Odumosu said, “Zelira is excited to have partnered with Levin Health in this innovative drug development project. We are thrilled that our world-class formulation and expertise in fast tracking drug developments has been born out with the Bellberry ethics approval for this phase 2 clinical trial. We look forward to continuing our partnership with Levin Health to validate a proprietary product that will help treat chronic pain."